Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial

Marie Sophie L.Y. de Koning; Paulien van Dorp; Solmaz Assa; Gabija Pundziute-Do Prado; Michiel Voskuil; Rutger L. Anthonio; Duco Veen; Tim Leiner; Anita J. Sibeijn-Kuiper; Harry van Goor; Dirk J. van Veldhuisen; Peter van der Meer; Robin Nijveldt; Erik Lipšic; Pim van der Harst

doi:10.1016/j.jacbts.2023.06.001

Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial

Marie Sophie L.Y. de Koning
, Paulien van Dorp
, Solmaz Assa
, Gabija Pundziute-Do Prado
, Michiel Voskuil
, Rutger L. Anthonio
, Duco Veen
, Tim Leiner
, Anita J. Sibeijn-Kuiper
, Harry van Goor
, Dirk J. van Veldhuisen
, Peter van der Meer
, Robin Nijveldt
, Erik Lipšic
, Pim van der Harst^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

3 Downloads (Pure)

Abstract

In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a first ST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo at arrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magnetic resonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomes were comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for large infarction.

Original language	English
Pages (from-to)	1285-1294
Number of pages	10
Journal	JACC. Basic to Translational Science
Volume	8
Issue number	10
DOIs	https://doi.org/10.1016/j.jacbts.2023.06.001
Publication status	Published - Oct 2023

Keywords

clinical trial
hydrogen sulfide
ischemia-reperfusion injury
myocardial infarction
randomized controlled trial
thiosulfates

Access to Document

10.1016/j.jacbts.2023.06.001Licence: CC BY

1-s2.0-S2452302X23002449-mainFinal published version, 966 KBLicence: CC BY

Cite this

de Koning, M. S. L. Y., van Dorp, P., Assa, S., Pundziute-Do Prado, G., Voskuil, M., Anthonio, R. L., Veen, D., Leiner, T., Sibeijn-Kuiper, A. J., van Goor, H., van Veldhuisen, D. J., van der Meer, P., Nijveldt, R., Lipšic, E., & van der Harst, P. (2023). Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial. JACC. Basic to Translational Science, 8(10), 1285-1294. https://doi.org/10.1016/j.jacbts.2023.06.001

@article{63a6125f1f77485b849033078636f34e,

title = "Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial",

abstract = "In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a first ST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo at arrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magnetic resonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomes were comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for large infarction.",

keywords = "clinical trial, hydrogen sulfide, ischemia-reperfusion injury, myocardial infarction, randomized controlled trial, thiosulfates",

author = "\{de Koning\}, \{Marie Sophie L.Y.\} and \{van Dorp\}, Paulien and Solmaz Assa and \{Pundziute-Do Prado\}, Gabija and Michiel Voskuil and Anthonio, \{Rutger L.\} and Duco Veen and Tim Leiner and Sibeijn-Kuiper, \{Anita J.\} and \{van Goor\}, Harry and \{van Veldhuisen\}, \{Dirk J.\} and \{van der Meer\}, Peter and Robin Nijveldt and Erik Lip{\v s}ic and \{van der Harst\}, Pim",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = oct,

doi = "10.1016/j.jacbts.2023.06.001",

language = "English",

volume = "8",

pages = "1285--1294",

journal = "JACC. Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier",

number = "10",

}

de Koning, MSLY, van Dorp, P, Assa, S, Pundziute-Do Prado, G, Voskuil, M, Anthonio, RL, Veen, D, Leiner, T, Sibeijn-Kuiper, AJ, van Goor, H, van Veldhuisen, DJ, van der Meer, P, Nijveldt, R, Lipšic, E & van der Harst, P 2023, 'Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial', JACC. Basic to Translational Science, vol. 8, no. 10, pp. 1285-1294. https://doi.org/10.1016/j.jacbts.2023.06.001

TY - JOUR

T1 - Sodium Thiosulfate in Acute Myocardial Infarction

T2 - A Randomized Clinical Trial

AU - de Koning, Marie Sophie L.Y.

AU - van Dorp, Paulien

AU - Assa, Solmaz

AU - Pundziute-Do Prado, Gabija

AU - Voskuil, Michiel

AU - Anthonio, Rutger L.

AU - Veen, Duco

AU - Leiner, Tim

AU - Sibeijn-Kuiper, Anita J.

AU - van Goor, Harry

AU - van Veldhuisen, Dirk J.

AU - van der Meer, Peter

AU - Nijveldt, Robin

AU - Lipšic, Erik

AU - van der Harst, Pim

PY - 2023/10

Y1 - 2023/10

N2 - In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a first ST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo at arrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magnetic resonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomes were comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for large infarction.

AB - In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a first ST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo at arrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magnetic resonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomes were comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for large infarction.

KW - clinical trial

KW - hydrogen sulfide

KW - ischemia-reperfusion injury

KW - myocardial infarction

KW - randomized controlled trial

KW - thiosulfates

UR - https://www.scopus.com/pages/publications/85173666167

U2 - 10.1016/j.jacbts.2023.06.001

DO - 10.1016/j.jacbts.2023.06.001

M3 - Article

AN - SCOPUS:85173666167

SN - 2452-302X

VL - 8

SP - 1285

EP - 1294

JO - JACC. Basic to Translational Science

JF - JACC. Basic to Translational Science

IS - 10

ER -

Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this